Seeking Alpha

HotDrStockNews'  Instablog

HotDrStockNews
Send Message
View HotDrStockNews' Instablogs on:
  • NHPR, AGEN, ONTY, NLST Stock Market Report from DrStockPick.com

    drstock-2-3

    signup3m

     

    http://pennyomega.com/img/nhpr.jpg

    National Health Partners, Inc. (OTCBB:NHPR), a leading provider of discount healthcare membership programs, announced recently the launch of a new network marketing program by one of its strategic partners, Xpress Healthcare, LLC.

    http://pennyomega.com/img/nhpr_highlight3.jpg

     

    Xpress Healthcare has teamed up with CARExpress in an effort to revolutionize the discount healthcare industry while at the same time bringing financial freedom to families across the nation. Xpress Healthcare has developed a first-class business platform that will enable brokers to develop their own business while generating strong monthly cash flows. Thru their unique website, www.join.xpressabo.com, brokers will be able to rapidly build their own independence.

    "By the end of the second quarter of 2011, Xpress Healthcare anticipates adding over 100 new brokers both participating in and promoting the CARExpress program whom we expect should enroll over 2,500 new members," states Ed Pettola, "and we expect our growth to accelerate in the 3rd quarter as we anticipate recruiting an additional 200 new brokers which should generate over 10,000 new CARExpress sales."

    "We are very excited about this new strategic partnership which we anticipate will have a major impact on our overall sales," states David M. Daniels, National Health Partners President and CEO. Mr. Daniels further states, "Offering tremendous growth potential, Xpress Healthcare is well positioned to become the leading marketing arm for CARExpress. By enrolling both new brokers as well as members, their growth should be explosive."

    National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress." CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company's primary target customer group is the 47 million Americans who have no health insurance of any kind. The company's secondary target customer group includes the millions of Americans who lack complete health insurance coverage. The company is headquartered in Horsham, Pennsylvania. For more information on the company, please visit its website at www.nationalhealthpartners.com.

    ****************

    Agenus Inc. (Nasdaq:AGEN) recently announced that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff") on March 3, 2011 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.

    Agenus Inc., a biotechnology company, develops and commercializes immunotherapies for cancer and infectious diseases. It markets Oncophage vaccine for the treatment of adjuvant renal cell carcinoma (kidney cancer).

    ****************

    Oncothyreon Inc. (Nasdaq:ONTY) recently announced that it conducted a conference call discussing its full year and fourth quarter 2010 financial results and provide a review of its pipeline of products in development on Thursday, March 10, 2011. An archive of the webcast is available on the Oncothyreon website.

    Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses primarily on the development of therapeutic products for the treatment of cancer.

    ****************

    Netlist Inc. (Nasdaq:NLST) recently reported financial results for the fourth quarter and fiscal year ended January 1, 2011. Revenues for the fourth quarter ended January 1, 2011, were $10.1 million, up 51 percent from revenues of $6.7 million for the fourth quarter ended January 2, 2010. Gross profit for the fourth quarter ended January 1, 2011, was $3.3 million, or 32.6 percent of revenues, up 94 percent from a gross profit of $1.7 million, or 25.1 percent of revenues, for the fourth quarter ended January 2, 2010.

    Netlist, Inc., together with its subsidiaries, engages in the design, manufacture, and sale of memory subsystems for the server, computing, and communication markets in the United States and the People’s Republic of China.

     

     

    THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

    Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 3,000,000 shares of (144) restricted common stock from the company and anticipates receiving 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (OTCPK:NHPR).

    drstbc

    Mar 12 1:09 PM | Link | Comment!
  • OXGND, CRWE, VLNC, ORFG, SAPX - Market Update From DrStockPick.com!

    drstock-2-3

    signup3m

    OXiGENE, Inc. (Nasdaq:OXGND) reported financial results for the year ending December 31, 2010. The Company also provided an update on recent clinical and corporate progress and outlook for 2011. For the year ended December 31, 2010, the consolidated net loss was $23.8 million, compared with a consolidated net loss of $28.9 million for 2009. The consolidated net loss for the year ended December 31, 2010 was impacted primarily by a reduction in operating expenses of approximately $12.7 million, offset by an $8.2 million fluctuation in the gain (loss) from the change in fair value of warrants and other financial instruments -- from a non-cash gain of approximately $2.2 million in the 2009 fiscal period to a noncash loss of approximately $6.0 million in the 2010 fiscal period. More At: http://drstockpick.com/?p=18347

    Mar 11 3:14 PM | Link | Comment!
  • AIRM, ACAD, NHPR, EPIC, SMRT, ALNY - Morning Market Watch, Videos Included, From DrStockPick.com!

    drstock-2-3

    signup3m

    http://pennyomega.com/img/airm.png AIRM, Air Methods Corp.

    Air ambulance service sometimes called Aeromedical Evacuation or simply Medevac is provided by a variety of different sources, in different places in the world.

    http://pennyomega.com/img/airm_highlight.png

    ***************************************************

    acad ACAD, ACADIA Pharmaceuticals Inc.

    ACAD is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACAD has a portfolio of four product candidates including pimavanserin, which is in Phase III development as a treatment for Parkinson’s disease psychosis. ACAD also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha.

    http://pennyomega.com/img/acad_highlight2.jpg

    Read More At: http://drstockpick.com/?p=18337

    Mar 11 1:03 PM | Link | Comment!
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.